Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States; Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, United States
Mai Wang
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Hui Zhu
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Steven H Phan
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Jason C Andrechak
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States; Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, United States
Alexander H Chang
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States; Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, United States
Nicholas M Ontko
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Tristan Marchena
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States
Physical Sciences Oncology Center at Penn, University of Pennsylvania, Philadelphhia, United States; Molecular and Cell Biophysics Lab, University of Pennsylvania, Philadelphia, United States; Bioengineering Graduate Group, University of Pennsylvania, Philadelphia, United States
Solid tumors generally exhibit chromosome copy number variation, which is typically caused by chromosomal instability (CIN) in mitosis. The resulting aneuploidy can drive evolution and associates with poor prognosis in various cancer types as well as poor response to T-cell checkpoint blockade in melanoma. Macrophages and the SIRPα-CD47 checkpoint are understudied in such contexts. Here, CIN is induced in poorly immunogenic B16F10 mouse melanoma cells using spindle assembly checkpoint MPS1 inhibitors that generate persistent micronuclei and diverse aneuploidy while skewing macrophages toward a tumoricidal ‘M1-like’ phenotype based on markers and short-term anti-tumor studies. Mice bearing CIN-afflicted tumors with wild-type CD47 levels succumb similar to controls, but long-term survival is maximized by SIRPα blockade on adoptively transferred myeloid cells plus anti-tumor monoclonal IgG. Such cells are the initiating effector cells, and survivors make de novo anti-cancer IgG that not only promote phagocytosis of CD47-null cells but also suppress tumor growth. CIN does not affect the IgG response, but pairing CIN with maximal macrophage anti-cancer activity increases durable cures that possess a vaccination-like response against recurrence.